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Macrophages play a critical role in the innate immune response to pathogen infection, but few tools exist for
systematic dissection of these responses using modern genome-wide perturbation methods. To develop an
assay platform for high-throughput analysis of macrophage activation by pathogenic stimuli, we generated
reporter systems in human and mouse macrophages with dynamic readouts for NF-kB and/or TNF-a
responses. These reporter cells show responsiveness to a broad range of TLR ligands and to gram-negative
bacterial infection. There are significant challenges to the use of RNAi in innate immune cells, including
efficient small RNA delivery and non-specific immune responses to dsRNA. To permit the interrogation of
the macrophage pathogen response pathways with RNAi, we employed the stably expressed reporter genes
to develop efficient siRNA delivery protocols for maximal target gene silencing with minimal activation of
the innate macrophage response to nucleic acids. We demonstrate the utility of these macrophage cell
systems for siRNA screening of pathogen responses by targeting components of the human andmouse TLR
pathways, and observe species-specific perturbation of signaling and cytokine responses. Our approach to
reporter cell development and siRNA delivery optimization provides an experimental paradigm with
significant potential for developing genetic screening platforms in mammalian cells.
M acrophages are central to the innate immune response to bacterial, parasitic and viral pathogens and theyrespond to these infectious stimuli through a range of pattern recognition receptors (PRRs) that interactwith conserved motifs, such as invariant structural components of bacterial cell walls (e.g., lipopoly-
saccharide (LPS) or peptidoglycan) or pathogen-specific nucleic acid motifs1–3. Classes of PRRs include the
membrane-associated toll-like receptors (TLRs), the cytosolic Nod-like receptors (NLRs), and the RIG-I-like
receptors (RLRs)4. Engagement of these host receptors leads to the activation of components in one ormore of the
nuclear factor kappa B (NF-kB), interferon regulatory factor (IRF), and mitogen activated protein kinase
(MAPK) dependent transcription factors families, leading to the subsequent expression of numerous inflam-
matory cytokines and immune mediators such as tumor necrosis factor-a (TNF-a) and type I interferons5.
The discovery of RNA interference (RNAi) and themajor advances in the understanding of small RNA biology
in the past decade have provided researchers with an invaluable tool for wide-scale and rapid genetic screening6,7.
RNAi takes advantage of the endogenous microRNA processing machinery to silence mRNA transcripts by
introduction of a short interfering (si)RNA complementary to the target gene mRNA, permitting the systematic
evaluation of gene product dependencies in a given biological system through targeted inhibition of gene
expression8. However, there are significant challenges to the use of this technology in innate immune cells,
including efficient small RNA delivery and non-specific immune responses to dsRNA9–13. These challenges have
led to very few reports of siRNA-based screens in innate immune cells as opposed to more easily employed
fibroblast or mesenchymal cell lines that do not have the same crucial roles in host defense as the macrophage.
In this study, we report the development of a highly optimized cell-based platform for siRNA screening in the
most commonly used human andmouse macrophage model cell lines, THP114 and RAW264.715. The engineered
macrophages provide readouts for NF-kB and/or TNF-a activation.We show that the stably integrated reporters
respond to a broad range of TLR ligands and to infection with the gram-negative bacterium, Burkholderia
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we identify protocols in both human and mouse macrophage cells
that achieve consistently high target gene knockdownwith no detect-
able non-specific dsRNA response. To validate this platform, we
targeted canonical components of the human and mouse TLR path-
ways with numerous independent siRNAs per gene, and dem-
onstrate perturbation of signaling and inflammatory cytokine
responses to specific TLR ligands.
Results
Development of a dual-promoter lentiviral expression system to
generate macrophage reporter cell lines for RNAi screening. To
allow the systematic functional testing of the components of PRR
signaling pathways in a relevant innate immune cell type, we first
developed a dual promoter lentiviral expression vector to establish
human and mouse macrophage cell lines expressing reporters
responsive to PRR activation (Fig. 1a). Our aim was to develop
dynamic readouts for the most typically activated signaling
pathway (NF-kB) and/or inflammatory cytokine (TNF-a)
responses to pathogenic stimuli, and to include means to correct
for cell number variation, which is particularly important for high-
throughput screening applications7,16. Using this lentiviral platform,
we created a RAW264.7 mouse macrophage cell line expressing two
fluorescent biosensors for ‘high content’ image-based screening
(RAW G9 clone; Fig. 1b–c). The first gene cassette expresses
GFP fused to the relA NF-kB transcription factor driven by its
endogenous promoter. This fusion protein partitions to the
cytoplasm in unstimulated cells, and translocates to the nucleus in
the first 40 min after activation with LPS (Fig. 1d, Supplementary
Videos 11 3). The second gene cassette contains the murine TNF-a
promoter driving expression of the red fluorescent protein mCherry,
Figure 1 | Generation of mouse and human macrophage TLR pathway reporter cell lines for siRNA screening applications. (a) Design of a dual-
promoter lentiviral vector for expression of TLR pathway reporters. (b1 c) Gene cassettes in themouse RAWG9 reporter clone containing (b) themouse
rela promoter driving expression of a GFP-relA fusion protein and (c) the mouse tnf promoter driving expression of an mCherry-PEST fusion protein.
(d) Cytosol-to-nuclear translocation of the GFP-relA fusion in RAWG9 cells up to 40 min after treatment with 10 ng/ml LPS (e) Increased tnf promoter-
driven mCherry expression in RAW G9 cells up to 16 hr after treatment with 10 ng/ml LPS (f) Gene cassettes in the human THP1 B5 reporter clone
containing the human UBC promoter driving constitutive expression of renilla luciferase and the human TNF promoter driving TLR ligand-inducible
expression of firefly luciferase. (g–h) Human TNF-a reporter responses in THP1 B5 cells differentiated with different doses of PMA for 72 hr, and
stimulated for 4 hr with a range of (g) LPS or (h) Lipid A doses. Data are representative of three experiments (g, h; mean1 s.d.). ***P, 0.001, ****P,
0.0001 (two-tailed t test).
www.nature.com/scientificreports
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fused to a destabilizing PEST sequence that reduces the protein’s
half-life in the cell to provide a dynamic readout of TNF-a
promoter activity. This biosensor shows a significant increase in
mCherry expression in response to LPS activation of the
engineered RAW G9 cells (Fig. 1e, Supplementary Videos 2 1 3).
We used a similar strategy to create a THP1 human monocyte cell
clone (THP1 B5) expressing firefly luciferase driven by the human
TNF-a promoter combined with renilla luciferase driven by a
ubiquitin promoter to provide a normalization factor for cell
number variability in assay wells (Fig. 1f). Thus, the firefly/renilla
ratio in this cell line after TLR stimulation provides a specific
measure of the human TNF-a promoter activity. THP1 cells
normally grow in suspension, but they can be differentiated into
an adherent and more macrophage-like state by treatment with
PMA14,17. This also induces increased expression of several key
macrophage functional genes such as CD14 and macrophage
scavenger receptors (data not shown). We found that the
concentration of PMA and length of incubation time led to
considerable differences in the fold-increase in signal from the
human TNF-a promoter reporter in the THP1 B5 cell line.
Activation of the human TNF-a promoter driven firefly luciferase
expression over a range of LPS doses was substantially higher after
72 hr of differentiation with a low concentration of 5 ng/ml PMA,
compared to either 50 or 500 ng/ml PMA concentrations (Fig. 1g). A
similar pattern of increased responsiveness at low PMA levels was
observed using the purified LPS component Lipid A (Fig. 1h), and is
consistent with previous reports of higher sensitivity in THP1 cells
differentiated with lowPMAconcentration18.Moreover, comparison
of the length of differentiation time showed the signal increase in
response to TLR ligand activation was more substantial after 48–
72 hr of differentiation than after 24 hr, presumably due to the
time required for the cells to adopt a more macrophage-like state
(data not shown). Thus, a 72 hr incubation with 5 ng/ml PMA was
selected as the optimal differentiation condition for the THP1 B5 cell
line.
Mouse and human macrophage reporter cell lines respond to a
broad range of TLR ligands. To assess the responsiveness of the
RAW G9 and THP1 B5 macrophage cell lines, we stimulated them
with a range of stimuli for different TLRs: Lipopolysaccharide (LPS;
TLR4), Pam3CSK4 (P3C; TLR2/1), Pam2CSK4 (P2C; TLR2/6),
peptidoglycan (PGN; TLR2/6), flagellin (FLG; TLR5), resiquimod
848 (R848; TLR7/8), CpG DNA (CpG; TLR9) and poly I5C (pI5C;
TLR3). We chose a range of 5–6 concentrations for each ligand to
assess dose-responsiveness (see Fig. 2 legend). The mouse macrophage
RAWG9 cells showed NF-kB and TNF-a reporter responses to all the
tested TLR ligands except flagellin and poly I5C (Fig. 2a1 b). This is
consistent with microarray analysis of these cells that finds no
significant expression of either TLR5 or TLR3, but detectable
expression of the receptors for the other tested TLR ligands
(Supplementary Fig. 1). The human macrophage THP1 B5 cells
show a TNF-a reporter response to all the tested TLR ligands
except CpG and pI5C (Fig. 2c), which is again consistent with
undetectable transcript levels for their respective receptors, TLR9
and TLR3 in both parental THP1 cells and the THP1 B5 reporter
clone (Supplementary Fig. 1).
Based on the dose-response data for the TLR ligands that gave
responses in the RAW G9 and THP1 B5 reporter cells, we selected
single ligand concentrations and assessed time-courses of activation
for each reporter readout. In the mouse RAW G9 cells, the NF-kB
response to LPS, P3C, P2C and R848 showed similar kinetics with a
peak in the nuclear/cytosolic relA ratio at around 40 min (Fig. 3a). In
contrast, the response to CpG showed slower kinetics with a peak
closer to 2 hr (Fig. 3b), possibly due to the time required for this
ligand to fully activate the endosomal TLR9 receptor. However, it is
noteworthy that the receptor for R848 (TLR7 or TLR8) is also endo-
somal, but is activated with faster kinetics (Fig. 3b). The TNF-a
reporter response in the RAW G9 cells peaked around 16 hr for
LPS, P3C, P2C and R848 (Fig. 3c). Although the initial rate of activa-
tion of the TNF-a reporter by CpG was slower, consistent with the
slower activation of NF-kB (Fig. 3b), the peak of TNF-a reporter
activation was still reached at 16 hr, albeit to a lower maximum level
than the other TLR ligands (Fig. 3d). We have previously shown that
the PEST sequence, which confers a half-life of approximately 1 hr
on the mCherry reporter protein, allows for a close correlation
between mCherry intensity and synthesis rate, such that the mea-
sured fluorescence provides a dynamic reflection of TNF-a promoter
activity19. This prior study also demonstrated that upon TLR activa-
tion of the RAW G9 clone, the nuclear/cytosolic relA ratio dimin-
ished close to basal levels by 5 hr after activation, while the TNF-a
reporter signal was reduced after 24 hr19. In the human THP1 B5
cells, we observed a faster activation of the TNF-a luciferase reporter,
with a signal peak at 4 hr (Fig. 3e). This could reflect faster activation
kinetics of the TNF-a promoter in human cells and/ormore sensitive
detection of the firefly luciferase readout compared to mCherry
fluorescence.
Mouse and humanmacrophage reporter cell lines respond to gram-
negative bacterial infection. To assess whether the reporters in the
described human and mouse macrophage cells were responsive to
pathogen infection, we challenged the cells with the gram-negative
bacterium Burkholderia cenocepacia. Strains of the B. cenocepacia
complex are opportunistic pathogens that can cause serious
infections in immune compromised patients, particularly those
suffering from cystic fibrosis (CF) or chronic granulomatous disease
(CGD)20–24. We infected the human THP1 B5 cells with increasing
MOIs of two different bacterial strains that have been isolated from
infected patients, J2315 and K56-2. In both cases, we observed a
bacterial MOI-dependent increase in the activation of the human
TNF-a reporter (Fig. 4a 1 b). In a 24 hr time course, the peak
reporter activation was usually observed at 24 hr for both strains,
except at a high MOI of 100 for the J2315 strain, which showed
peak activation at 8 hr. In previous work, we have shown that at an
MOI of 1, the J2315 strain escapes the host endosome and begins to
replicate in the cytosol by 8 hr, reaching a peak of replication at 20–
24 hr25. This is consistent with the reporter activation kinetics
observed at low and moderate MOIs of 1 and 10. We also observed
up to 4-fold activation of the human TNF-a reporter with a high MOI
of formalin killed (FK) bacteria. Although killed bacteria cannot
replicate in the host cell, the activation of the TNF-a reporter at
early time points by FK bacteria is consistent with presence of TLR
ligands on the killed bacterium surface, while the activation at later
times could correlate with the detection of bacterial nucleic acid
PAMPs upon bacterial degradation, as we have previously observed
significant colocalization of FK bacteria with lysosomal markers at
these time points25.
Infection of the mouse RAW G9 cells with B. cenocepacia also led
to activation of the stably expressedNF-kB and TNF-a reporters.We
observed a bacterial dose and time-dependent increase in tnf pro-
moter-drivenmCherry expression with the live J2315 strain, but only
a very slight TNF-a reporter increase with killed bacteria (Fig. 4c).
We also observed rapid p65/relA translocation to the nucleus in
response to B. cenocepacia infection, especially at high bacterial
MOI (Fig. 4d). Interestingly, while formalin killed bacteria induced
very little TNF-a promoter activation, NF-kB activation was com-
parable to that observed with live bacteria (Fig. 4d), suggesting that
the initial NF-kB translocation is not in itself sufficient to drive the
high level TNF-a promoter activation observed at later time points
(Fig. 4c).
Use of constitutively expressed reporter genes for siRNA delivery
optimization. Effective delivery of siRNA into hematopoietic cells
remains a significant obstacle to the implementation of effective
www.nature.com/scientificreports
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siRNA-based host pathogen RNAi screens. To establish a
reproducible method that could achieve robust knockdown (KD)
of target genes and reduce false negative frequency in screening,
we took advantage of the fact that the reporter cell lines described
above provide convenient control siRNA targets in the form of the
GFP and renilla luciferase reporters they express (Fig. 1b 1 f).
Optimizing siRNA delivery by targeting these reporters allows
measurement of protein rather than mRNA KD (the latter being
Figure 2 | TLR ligand dose responses inmouse and humanmacrophage reporter cell lines. (a1 b)Dose response of (a) cytosol-to-nuclear translocation
of the GFP-relA fusion at 30 min (120 min for CpG) and (b) tnf promoter-driven mCherry expression at 12 hr after treatment of RAW G9 cells
with LPS (0, 0.5, 1, 5, 12.5 and 25 ng/ml), P3C (0, 62.5, 125, 250, 500 and 1000 nM), P2C (0, 7.8, 31.25, 62.5, 125 and 250 nM), PGN (1, 15, 37.5, 75, 150
and 300 ng/ml), FLG (0, 0.1, 1, 10, 100 and 1000 ng/ml), R848 (0, 0.37, 0.75, 1.5, 3 and 6 mM), CpG (0, 0.35, 0.7, 1.4, 2.8 and 5.6 mg/ml) or pI5C (0, 12.5,
25 and 50 mg/ml). (c) Dose response of the TNF firefly/UBC renilla luciferase expression ratio in THP1 B5 cells at 4 hr after treatment with LPS (0, 0.1, 1,
10 and 100 ng/ml), P3C (0, 1, 10, 100 and 1000 nM), P2C (0, 0.1, 1, 10 and 100 nM), PGN (0, 1, 10 and 100 mg/ml), FLG (0, 1, 10, 100 and 1000 ng/ml),
R848 (0, 0.1, 1, 10 and 50 mg/ml), CpG (0, 1, 10, 100 and 1000 nM) or pI5C (0, 1, 10 and 100 mg/ml). Data are representative of three experiments (a–c;
mean 1 s.d.). **P , 0.01, ***P , 0.001, ****P , 0.0001 (two-tailed t test).
www.nature.com/scientificreports
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Figure 3 | TLR ligand response kinetics of mouse and human macrophage reporter cell lines. (a–d) Time course of (a 1 b) cytosol-to-nuclear
translocation of the GFP-relA fusion and (c1 d) Tnf promoter-driven mCherry expression in RAWG9 cells after treatment with (a1 c) 10 ng/ml LPS,
250 nMP3C, 125 nMP2C and 3 mMR848 and (b1 d) 100 nMCpG and 3 mMR848. (e) Time course of theTNF firefly/UBC renilla luciferase expression
ratio in THP1 B5 cells after treatment with 10 ng/ml LPS, 100 nM P3C, 10 nM P2C, 10 mg/ml PGN and 10 mg/ml R848. Data are representative of three
experiments (a–e; mean 1 s.d.)
www.nature.com/scientificreports
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the most common validation method for siRNA delivery), providing
a more direct assessment of the required endpoint needed for an
effective screen. We first designed and tested four candidate siRNA
sequences against the GFP and renilla luciferase coding sequences,
and identified multiple potent siRNAs for each target (Fig. 5a). The
most effective siRNAs against each target gene were pooled for
testing siRNA delivery conditions in the RAW G9 and THP1 B5
reporter cells. By conducting the testing in 384-well plates we
could readily examine an extensive matrix of transfection
conditions (Fig. 5b), which improved the chances of identifying
optimal siRNA delivery protocols for the macrophage reporter cell
lines. Using this approach, we identified reproducible lipid-based
transfection protocols that gave 80–95% target knockdown for
both the GFP in the RAW G9 clone (Fig. 5c 1 d) and the renilla
luciferase in the THP1 B5 reporter cell line (Fig. 5f 1 g). Since TLR
ligand preparations can be prone to contamination with LPS, we
used these optimized siRNA transfection protocols to confirm that
the cell line reporter responses to the panel of TLR ligands tested in
Figures 2 and 3were not caused by trace amounts of LPS in the ligand
preparations. We targeted the TLR4 gene in both the THP1 B5 and
RAWG9 reporter cells with a specific siRNApool, and found that the
reporter responses were only perturbed after treatment of the cells
with LPS (Supplementary Fig. 2).
Because the response to dsRNA during pathogen infection is very
robust in macrophages and a strong subsequent interferon response
would be problematic for the interpretation of effects resulting from
gene-specific siRNA knockdown, we also looked for any interferon
response to the transfected siRNA. Using the identified optimal
transfection conditions, we found no significant elevation in type-I
interferon production from either the RAW G9 or THP-1 B5
reporter cell lines during our assay window of 48 to 72 hr post-
transfection (Fig. 5e 1 h).
Validation of themouse and humanmacrophage siRNA screening
platform by perturbation of TLR pathway gene targets. To further
assess the utility of the cell line reporters and the efficiency of the
optimized siRNA delivery protocols, we targeted a range of canonical
TLR pathway genes in both the human and mouse macrophage cell
lines with six different siRNA per gene (Supplementary Table 1), and
tested the reporter responses to TLR ligands.We observed significant
reduction in the reporter responses for specific ligand/target gene
combinations that were consistent with known TLR pathway
architecture (Fig. 6)1,5. In the human THP1 B5 cells, we observed
diminished responses to LPS with KD of TLR4, MD2, MyD88 and
Mal, to R848 with KD of TLR8 and MyD88 and to flagellin with KD
of TLR5 and MyD88 (Fig. 6a). In the mouse RAW G9 cells, we saw
the same specific perturbation of the LPS response as seen in the
human cells with KD of TLR4, MD2, MyD88 and Mal, and this was
seen for both TNF-a (Fig. 6b) and NF-kB (Fig. 6c) reporters. The
mouse cells also showed a perturbed R848 response withMyD88KD,
but in contrast to the human cells, TLR7 KD, but not TLR8, led to a
diminished R848 response for both TNF-a andNF-kB (Fig. 6B1C).
To confirm that the differential use of TLR7 and TLR8 in response to
R848 observed in the mouse and human macrophage cells was not
simply due to more efficient KD of the receptor for which the
phenotypic effect was observed, we measured the relative efficiency
of KD of both receptors in each cell type. This demonstrated that in
both the RAWG9 and THP1 B5 cells, comparable KD of both TLR7
and TLR8 was achieved (Supplementary Fig. 2). This suggests that
the human THP1 andmouse RAWmacrophage cell lines respond to
the R848 ssRNA mimic through different receptors. These results
also confirm the utility of the described cell lines and siRNA delivery
protocols to accurately profile gene dependencies in the TLR
signaling pathway using RNAi.
Discussion
Despite the discovery potential of RNAi technology, cells of the
innate immune system pose significant challenges for RNAi applica-
tion in terms of identifying conditions that achieve robust target gene
knockdown while avoiding a non-specific immune response to the
introduced dsRNA7,12,13. These challenges have led to the adoption of
surrogate non-immune model cells, often with over-expressed
pathogen receptors or pathway components, for host-pathogen
RNAi screens. The lack of concordance in gene hits for several
genome-wide screens for host factors involved in HIV26–28 and
influenza29–32 may be attributed to the use of different engineered,
non-hematopoietic cell lines as assay vehicles in such screens. One
also cannot be certain that the hits in these screens reflect aspects of
signaling pathways relevant to innate immune cells. For example,
we have found that there are important mechanisms of signaling
Figure 4 | Responses to gram-negative bacterial infection in mouse and
human macrophage reporter cell lines. (a 1 b) Dose response and time
course of the tnf firefly/ubc renilla luciferase expression ratio in THP1 B5
cells infected with either the (a) J2315 or (b) K56-2 strain of B. cenocepacia.
(c 1 d) Dose response and time course of the (c) tnf promoter-driven
mCherry expression and (d) cytosol-to-nuclear translocation of the GFP-
relA fusion in RAWG9 cells infectedwith the J2315 strain ofB. cenocepacia.
MOI: Multiplicity of infection (bacteria per cell). FK: formalin-killed
bacteria. Data are representative of two experiments (a–d; mean 1 s.d.).
**P , 0.01, ***P , 0.001, ****P , 0.0001 (two-tailed t test).
www.nature.com/scientificreports
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feedback control in macrophages challenged with different doses of
bacterial LPS that are not evident in fibroblasts19.
We describe here the development of macrophage cell lines with
stably integrated expression of multiple reporter genes responsive to
pathogenic stimuli. These include amouse reporter line derived from
RAW264.7 cells that expresses high content imaging readouts for
both NF-kB cytosol to nuclear translocation and a TNF-a transcrip-
tional reporter, and a human line derived from THP-1 cells that
combines human TNF-a promoter driven firefly luciferase with a
constitutively expressed renilla luciferase that provides a normaliza-
tion control for changes in cell number or transcription flux. The
latter design is helpful in endpoint screening assays to filter out hits
Figure 5 | Optimization of siRNA delivery protocols for the RAW G9 and THP1 B5 macrophage reporter cell lines that avoid non-specific
immunostimulatory responses. (a) Identification of optimal siRNAs targeting the GFP and renilla genes. Control or GFP/renilla siRNAs were co-
transfected into HEK293 cells with GFP or renilla expression plasmids. Relative GFP or renilla reporter gene expression levels were measured at 48 hr
post-transfection. GFP siRNAs 1, 2 and 4 and renilla siRNAs 1–4 were pooled for use in subsequent siRNA delivery optimization experiments in RAWG9
and THP1 B5 cells respectively (b) Experimental test matrix in 384-well format for siRNA delivery protocol optimization. Column variables are different
volumes (see Methods) of the following transfection lipids: Dharmafect 1–4 (Dh1–4), Hiperfect (Hiper), RNAiMax (RMax), Transit TKO (TKO) and
Lipofectamine LTX (LTX). Row variables are siRNA concentration (10–100 nM), siRNA/lipid dilution buffer (OptiMEM or dulbecco’s PBS) and cell
density (1 5 5,000 cells/well, 2 5 10,000 cells/well). (c) Effect on GFP-relA expression in RAW G9 reporter cells transfected with the GFP siRNA pool
validated in panel a using the conditionmatrix in panel bmeasured at 72 hr post-transfection. Best knockdownwith no effect on cell viability seen in plate
position P21 (red square). (d) Optimized Transit TKO lipid delivery of GFP siRNA pool to RAWG9 cells in 384-well format leads to reproducible GFP-
relA intensity reduction of.80%. (e) Measurement of IfnbmRNA induction over time in RAWG9 cells transfected with either Transit TKO lipid alone
or control siRNA via the optimized Transit TKO delivery protocol. Cells treated with lipid 1 5 mg/ml poly I5C are a positive control for robust Ifnb
induction. (f) Effect on renilla expression in THP1 B5 reporter cells transfected with the renilla siRNApool validated in panel a using the conditionmatrix
in panel bmeasured at 72 hr post-transfection. Best knockdownwith no effect on cell viability seen in plate position C15 (red square). Grey squares5 low
cell viability. (g) Optimized Hiperfect lipid delivery of renilla siRNA to THP1 B5 cells in 384-well format leads to reproducible renilla expression
reduction of.90%. (h) Measurement of IFNBmRNA induction in THP1 B5 cells transfected with either Hiperfect lipid alone or control siRNA via the
optimized Hiperfect delivery protocol. Cells treated with lipid 1 5 mg/ml poly I5C are a positive control for robust IFNB induction. Data are
representative of two experiments (a, e, h; mean 1 s.d.). **P , 0.01, ***P , 0.001, ****P , 0.0001 (two-tailed t test).
www.nature.com/scientificreports
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that affect cell viability or general transcriptional processes. The
described cell lines are responsive to almost all TLR ligands tested,
in addition to intact bacteria, proving valuable model cell systems for
studies of PRR pathway dependencies in both mouse and human
macrophage responses to pathogens. Moreover, the dual high con-
tent readout in the mouse RAWG9 cells also provides opportunities
for live cell imaging and single cell analysis that we have previously
shown can identify aspects of feedback control in NF-kB transcrip-
tional responses and LPS dose encoding that would not have been
possible from bulk cell analyses19.
To address the problematic nature of macrophages with respect to
siRNA delivery, our use of the stably expressed reporter genes (intro-
duced during generation of our reporter assays) as siRNA targets
allowed us to test several hundred transfection conditions in a single
384-well assay plate. This showed that even notoriously difficult to
transfect cells were conducive to efficient siRNA delivery if enough
conditions were tested. It should be noted however that the condi-
tions we identified in 384-well format do not necessarily scale
directly into other plate formats, and we have found that it is neces-
sary to test subtle variations of the optimized 384 well condition to
achieve similar results in alternative well sizes.
The initial discovery of siRNA-based gene perturbation in mam-
malian cells suggested that the host interferon response to dsRNA
could be avoided as long as the dsRNA shorter than 20–25 nt8.
However, later studies demonstrated that dsRNA responses could
still occur using short oligonucleotides through PRR activation in
innate immune cells that are particularly sensitive to nucleic acid
stimuli12,13. There are also previous reports of mouse macrophage
activation in response to certain transfection lipids and to non-tar-
geting siRNA33. The screening of hundreds of transfection conditions
allowed us to identify siRNA/lipid combinations that showed min-
imal type I interferon induction and no elevation in interferon
expression during the typical assay window of 24–72 hr after
siRNA transfection.
Since the cell reporter systems we describe here are based on
transformed cell lines, it should be noted that these cells could have
peculiarities that are not reflective of the properties of primary
human or mouse macrophages. It is therefore important to validate
Figure 6 | Effects of knockdown of TLR pathway genes on specific ligand responses in mouse and human macrophage reporter cell lines. (a) Human
TNF-a reporter responses in THP1 B5 cells transfected with either non-targeting control or TLR pathway gene-specific siRNAs and treated for 4 hr with
either 10 ng/ml LPS, 10 mg/ml R848 or 10 ng/ml FLG. (b) tnf promoter-driven mCherry expression at 16 hr and (c) Cytosol-to-nuclear translocation of
theGFP-relA fusion at 40min inRAWG9 cells transfectedwith either non-targeting control or TLRpathway gene-specific siRNAs and treatedwith 10 ng/
ml LPS or 3 mM R848. 6 individual siRNAs per gene were used (Supplementary Table 1) and the average reporter response calculated. Data are
representative of two experiments and reporter responses are normalized to the levels observed with non-targeting control siRNA (a–c; mean1 s.d.). **P
, 0.01, ***P , 0.001, ****P , 0.0001 (two-tailed t test).
www.nature.com/scientificreports
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findings made in such cell lines with studies in primary cells.
However, the cell lines employed here are the most widely used in
vitromodel systems for mouse (RAW264.7) or human (PMA-differ-
entiated THP1) macrophage-like cells, and as we demonstrate, they
are responsive to a wide range of TLR ligands. The described cell
system is also limited to readouts of NF-kB activation and TNF-a
promoter induction, however the methods used for stable reporter
expression can be readily applied to additional signaling and tran-
scriptional readouts.
In testing our described screening platforms through siRNA
knockdown of select receptors and proximal signaling components
in the human and mouse TLR pathways, we observed the expected
specificity for TLR4 andMD2with LPS and TLR5 with flagellin1.We
also observed differences in the receptor requirements for the R848
response, with TLR8 required in human cells and TLR7 in mouse.
This is consistent with prior observations, and may suggest species
differences in how ssRNA is sensed in the endosome of human and
mousemacrophages34,35. Among proximal signaling components, we
identified the expected requirement of MyD88 for all ligands tested,
and the selective use of Mal/Tirap in the LPS response but not for
either flagellin or R8481.
In summary, the human andmousemacrophage reporter cells and
optimized siRNA delivery protocols provide an experimental plat-
form with significant potential for genetic screening in an innate
immune cell type that is highly relevant for host pathogen studies.
Furthermore, the development of cell systems in both human and
mouse macrophage cell lines will permit a comparison of similarities
and differences in how innate cells from the two species respond to
pathogenic stimuli.
Methods
Generation of mouse and human macrophage reporter cell lines. Construction of
the lentiviral plasmid expressing the dual GFP-RelA and tnf promoter mCherry-
PEST reporters (Fig. 1b–e) and the infection of RAW264.7 cells with lentivirus to
generate the RAW G9 cell clone has been previously described19. To construct the
human tnf promoter dual luciferase reporter (Fig. 1f), the sequence expressing the
renilla luciferase hRlucP gene was excised from the pGL4.71 plasmid (Promega) and
used to create a lentiviral plasmid with the ubc promoter driving expression of
hRluc2P-IRES-Neo as described previously36. The sequence from 21110 to 250 of
the human tnf promoter was cloned by PCR from THP1 cells and ligated upstream of
the firefly luciferase luc2P gene in the pGL4.11 plasmid (Promega). A fragment
containing the human tnf promoter–luc2P–SV40 polyA sequence was excised from
this plasmid and inserted upstream of the ubc promoter in the UbcP-hRluc2P-IRES-
Neo plasmid described above. Recombinants were screened for the reverse
orientation of the human tnf promoter–luc2P–SV40 polyA gene cassette 1 relative to
the ubc promoter-hRlucP-IRES-Neo gene cassette 2 (Fig. 1a). Lentiviral particles were
generated and used to infect the human THP1monocytic leukemia cell (ATCC, TIB-
20) cells as previously described. The infected cells weremaintained in the presence of
G418 selection followed by dilution-cloning to isolate individual cell clones. Single
cell clones were isolated, expanded and screened for robust firefly luciferase response
to a TLR ligand panel (Fig. 2c). A single clone (B5) was chosen for all subsequent
experiments.
High content imaging of RAW G9 mouse macrophage cells. The GFP-p65 and
TNF-a promoter-mCherry reporters were imaged in the RAWG9 reporter cell clone
using a BD Pathway 855 bioimager (BD biosciences). BD AttoVision software was
used to automatically identify and quantify DAPI-stained cell nuclei, GFP-p65 and
mCherry fluorescence. GFP located within the area of the nuclear staining (eroded by
2 pixels) was defined as nuclear NF-kB, while GFP within a 2-pixel-wide ring around
the nuclear staining was defined as cytosolic NF-kB. For determination of NF-kB
translocation, the ratio of nuclear to cytoplasmic GFP-p65 intensity was calculated
using BD Image Data Explorer software. For mCherry expression, nuclear mCherry
was quantified using the same method as for NF-kB. Background was subtracted and
average intensity was used as ameasure of TNF-a promoter activity. Live cell imaging
of RAW G9 cells expressing GFP-p65 and tnf promoter driven mCherry for
Supplementary Videos 1–3 was carried out as previously described19.
Dual luciferase assay of THP1 B5 human macrophage cells. The human THP1 B5
cell clone was differentiated into a macrophage-like state in RPMI 1640 medium
containing varying concentrations of phorbol-12-myristate-13-acetate (PMA, from
Sigma, P1585) for 72 h during protocol development andwith 5 ng/ml of PMA for all
remaining experiments. The differentiated cells were treated with TLR ligands for
activation or growth media as control. After stimulation, the cells were washed once
in PBS, and lysed in passive lysis buffer (Promega). Firefly and renilla luciferase
activity in the cell lysates was determined using the Dual-Luciferase Reporter Assay
System (Promega, E1960), following the manufacturers protocol, and the ratio of
firefly luminescence to renilla luminescence was used to reflect the cell response to
stimulation.
Cell culture andTLR ligand stimulation.RAWG9 cells weremaintained inDMEM,
10% FBS, 20 mM Hepes, and 2 mM glutamine. THP1 B5 cells were maintained in
RPMI1640, 10% FBS, and 2 mM glutamine containing 500 ug/ml G418. TLR ligand
sources: LPS was from Alexis Biochemicals, Salmonella minnesota R595 TLRgrade,
ALX-581-008-L002; Pam3CSK4 (P3C) was from EMCMicrocollections, cat# L2000;
PGNwas from Sigma, peptidoglycan from Staphylococcus aureus, Cat.# 77140; R848
was from InvivoGen, tlrl-r848; Pam2CSK4 (P2C) was from EMC Microcollections,
cat# L2020; Flagellin was from Invivogen, FLA-ST ultrapure, tlrl-epstfla; Lipid A was
from Avanti Polar Lipids, 699500P; CpG was from IDT; poly I5C was from
Invivogen, tlrl-picw.
Gram-negative bacterial infection. Infection of both human THP1 B5 and mouse
RAW G9 cells with B. cenocepacia was conducted using the infection method
previously described for primary macrophages and THP-1 cells25.
Optimization of siRNA delivery to RAW G9 and THP1 B5 cells. The following
sequences in the EGFP and renilla luciferase coding regions were targeted with
custom synthesized siRNA (Dharmacon); EGFP siRNA1
GCCACAACGTCTATATCAT, siRNA2 GCGCCGAGGTGAAGTTCGA, siRNA3
GAGCTGGACGGCGACGTAA and siRNA4 GCATCGAGCTGAAGGGCAT and
renilla siRNA1 CAAGCAAGATCATGCGGAA, siRNA2
CCGAGTTCGTGAAGGTGAA, siRNA3 CAGATGAAATGGGTAAGTA and
siRNA4 GGCCTTTCACTACTCCTAC. The potency of the individual siRNA
sequences was assessed by co-expression in HEK293 cells with plasmids expressing
GFP (pEGFP-N1 (Clontech)) or renilla (pGL4.74 (Promega)) and measuring the
effect on GFP/renilla expression compared to cells transfected with a non-targeting
control siRNA (NTC5; Dharmacon). Validated siRNA pools against GFP and renilla
were generated by combining EGFP siRNAs 1, 2 and 4 and renilla siRNAs 1, 2, 3 and
4. The following transfection lipids and volumes (per well of 384 well plate) were
tested in the optimization of siRNA delivery to RAWG9 and THP1 B5 reporter cells;
Dharmafect 1 to 4/0.03–0.14 ml (Dharmacon), Hiperfect/0.125–0.25 ml (Qiagen),
RNAiMax/0.025–0.075 ml and Lipofectamine LTX/0.04–0.15 ml (Life Technologies)
and TransitTKO/0.04–0.2 ml (Mirus Biology LLC). Opti-MEM I and Dulbecco’s
phosphate buffered saline (DPBS) buffers were purchased from Life Technologies.
Across thematrix of transfection conditions detailed in Fig. 5b, knockdown efficacy of
GFP expression in RAWG9 cells wasmeasured by average cytoplasmic GFP intensity
quantified by high content imaging, and knockdown efficacy of renilla luciferase
expression in THP1 B5 cells was measured using the Dual-Luciferase Reporter Assay
System (Promega, E1960). The following optimized protocols were established for
subsequent siRNA screening assays in 384-well plates: RAWG9 cells; 2 ml of 2.5 mM
siRNA (final transfection concentration of 100 nM) stock was added per well. A pre-
mix of 0.2 ml Transit TKO and 7.8 ml DPBS per well was prepared and added to the
siRNA. Plates were shaken for 1 min and then incubated at room temperature for
20 min. 5,000 RAW G9 cells in 40 ml media were added per well and incubated at
37uC in a humidified atmosphere with 5% CO2 for 48 hr. Mediumwas replaced prior
to ligand stimulation and high content assay measurement. THP1 B5 cells; 2 ml of
1.25 mMsiRNA (final transfection concentration of 50 nM) stock was added per well.
A pre-mix of 0.2 ml Hiperfect and 7.8 ml Opti-MEM I was prepared and incubated at
room temperature for 5 min. The lipid pre-mix was added to siRNA in the well and
incubated a further 20 min. To each well, 5,000 THP1 B5 cells in 40 ml cRPMI
medium containing PMA (5 ng/ml final concentration) were added and incubated at
37uC in a humidified atmosphere with 5% CO2 for 68 hr prior to ligand stimulation
and dual luciferase assay.
Quantitative PCR (qPCR). Total RNA was extracted with the RNeasy Micro Kit
(Qiagen, 74004) and RNeasy Mini Kit (Qiagen, 74106). cDNA was synthesized from
extracted RNA with iScript cDNA Synthesis Kit (Bio-rad, 170-8891). Quantitative
RT-PCR was performed with Thermo Scientific Solaris qPCR Rox Master Mix (AB-
4351/C) or with Power SYBR green PCR Master Mix (Applied biosystems, Cat. No.
43091655) with a Mastercycler realplex4 real-time PCR detection system
(Eppendorf), according to the manufacturers’ protocols. The abundances of the
mRNAs of interest in each sample were normalized to that of b-actin or Hprt mRNA,
and fold changes in target mRNAs relative to their basal abundances were calculated
by the 22DDCt method. The primers and probes for human and mouse TLR7 and
TLR8 were purchased from GE Healthcare, Dharmacon (Solaris Mouse or Human
qPCRGene Expression Assay). The primers for human andmouse IFNb, b-actin and
Hprt were purchased from Qiagen (QuantiTech Primer Assays).
Targeting of TLR pathway components with siRNA. TLR pathway genes were
targeted with 6 unique siRNA sequences (3 each from Ambion and Qiagen) per gene
(Supplementary Table S1) and individual siRNAs were arrayed in 384-well plates.
Negative control siRNAs were from Dharmacon (Non-targeting controls; NTC#2, 3
or 5). LPS contamination of the TLR ligand panel was tested using siGenome
SMARTpool siRNAs against human andmouse TLR4 (GE Healthcare, Dharmacon).
After siRNA transfection following the optimized protocols above, THP1 B5 cells
were stimulated with TLR ligands for 4 hr and subjected to dual luciferase assay.
Replicate siRNA plates were run for RAWG9 cells to permit TLR ligand treatment of
www.nature.com/scientificreports
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one plate set for 40 min (NF-kB readout) and the second plate set for 16 hr (TNF-a
reporter readout). RAW G9 cells were fixed in 4% paraformaldehyde (Polyscience,
Inc) and nuclei were stained with 600 nM DAPI (Invitrogen) prior to high content
imaging. The reporter responses weremeasured for cells transfectedwith each of the 6
individual siRNAs/gene, and the average values were calculated.
Microarray analysis. Total RNA was isolated from RAW G9, parental RAW264.7,
THP1 B5 and parental THP1 cells with an RNeasy Mini Kit (Qiagen). Duplicate
biological were run for each cell line. Amplification and labeling of complementary
RNA (cRNA) was performed with the Illumina TotalPrep RNA Amplification Kit
(Invitrogen), and the cRNAs were hybridized to Illumina microarrays according to
the manufacturer’s protocol. A detection p value threshold of 0.1 was used to predict
presence or absence of TLR family genes.
1. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity.
Cell 124, 783–801, doi:10.1016/j.cell.2006.02.015 (2006).
2. Beutler, B. A. TLRs and innate immunity. Blood 113, 1399–1407, doi:10.1182/
blood-2008-07-019307 (2009).
3. Foster, S. L. & Medzhitov, R. Gene-specific control of the TLR-induced
inflammatory response. Clinical immunology 130, 7–15, doi:10.1016/
j.clim.2008.08.015 (2009).
4. Creagh, E. M. &O’Neill, L. A. TLRs, NLRs and RLRs: a trinity of pathogen sensors
that co-operate in innate immunity. Trends in immunology 27, 352–357,
doi:10.1016/j.it.2006.06.003 (2006).
5. Ostuni, R., Zanoni, I. & Granucci, F. Deciphering the complexity of Toll-like
receptor signaling. Cellular and molecular life sciences: CMLS 67, 4109–4134,
doi:10.1007/s00018-010-0464-x (2010).
6. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature 391, 806–811, doi:10.1038/35888 (1998).
7. Boutros, M. & Ahringer, J. The art and design of genetic screens: RNA
interference. Nat Rev Genet 9, 554–566, doi:10.1038/nrg2364 (2008).
8. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference
in culturedmammalian cells.Nature 411, 494–498, doi:10.1038/35078107 (2001).
9. Alexopoulou, L., Holt, A. C.,Medzhitov, R. & Flavell, R. A. Recognition of double-
stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413,
732–738, doi:10.1038/35099560 (2001).
10. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like
receptor 7 and 8. Science 303, 1526–1529, doi:10.1126/science.1093620 (2004).
11. Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor
7. Proc Natl Acad Sci U SA 101, 5598–5603, doi:10.1073/pnas.0400937101 (2004).
12. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate
immune response by synthetic siRNA. Nat Biotechnol 23, 457–462, doi:10.1038/
nbt1081 (2005).
13. Cekaite, L., Furset, G., Hovig, E. & Sioud, M. Gene expression analysis in blood
cells in response to unmodified and 2’-modified siRNAs reveals TLR-dependent
and independent effects. Journal of molecular biology 365, 90–108, doi:10.1016/
j.jmb.2006.09.034 (2007).
14. Tsuchiya, S. et al. Establishment and characterization of a human acutemonocytic
leukemia cell line (THP-1). International journal of cancer. Journal international
du cancer 26, 171–176 (1980).
15. Raschke,W. C., Baird, S., Ralph, P. &Nakoinz, I. Functional macrophage cell lines
transformed by Abelson leukemia virus. Cell 15, 261–267 (1978).
16. Birmingham, A. et al. Statistical methods for analysis of high-throughput RNA
interference screens. Nat Methods 6, 569–575, doi:10.1038/nmeth.1351 (2009).
17. Fleit, H. B. & Kobasiuk, C. D. The humanmonocyte-like cell line THP-1 expresses
Fc gamma RI and Fc gamma RII. Journal of leukocyte biology 49, 556–565 (1991).
18. Park, E. K. et al. Optimized THP-1 differentiation is required for the detection of
responses to weak stimuli. Inflammation research: official journal of the European
Histamine Research Society… [et al.] 56, 45–50, doi:10.1007/s00011-007-6115-5
(2007).
19. Sung, M. H. et al. Switching of the relative dominance between feedback
mechanisms in lipopolysaccharide-induced NF-kappaB signaling. Sci Signal 7,
ra6, doi:10.1126/scisignal.2004764 (2014).
20. Vandamme, P. et al. Occurrence of multiple genomovars of Burkholderia cepacia
in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J
Syst Bacteriol 47, 1188–1200 (1997).
21. Nzula, S., Vandamme, P. & Govan, J. R. Influence of taxonomic status on the in
vitro antimicrobial susceptibility of the Burkholderia cepacia complex.
J Antimicrob Chemother 50, 265–269 (2002).
22. Bernhardt, S. A., Spilker, T., Coffey, T. & LiPuma, J. J. Burkholderia cepacia
complex in cystic fibrosis: frequency of strain replacement during chronic
infection. Clinical infectious diseases: an official publication of the Infectious
Diseases Society of America 37, 780–785, doi:10.1086/377541 (2003).
23. Coenye, T. & LiPuma, J. J. Population structure analysis of Burkholderia cepacia
genomovar III: varying degrees of genetic recombination characterize major
clonal complexes. Microbiology 149, 77–88 (2003).
24. Mahenthiralingam, E., Urban, T. A. & Goldberg, J. B. The multifarious,
multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3, 144–156,
doi:10.1038/nrmicro1085 (2005).
25. Al-Khodor, S. et al. Burkholderia cenocepacia J2315 escapes to the cytosol and
actively subverts autophagy in human macrophages. Cellular microbiology 16,
378–395, doi:10.1111/cmi.12223 (2014).
26. Brass, A. L. et al. Identification of host proteins required forHIV infection through
a functional genomic screen. Science 319, 921–926, doi:10.1126/science.1152725
(2008).
27. Konig, R. et al. Global analysis of host-pathogen interactions that regulate early-
stage HIV-1 replication. Cell 135, 49–60, doi:10.1016/j.cell.2008.07.032 (2008).
28. Zhou, H. et al. Genome-scale RNAi screen for host factors required for HIV
replication. Cell Host Microbe 4, 495–504, doi:10.1016/j.chom.2008.10.004
(2008).
29. Brass, A. L. et al. The IFITM proteins mediate cellular resistance to influenza A
H1N1 virus,West Nile virus, and dengue virus. Cell 139, 1243–1254, doi:10.1016/
j.cell.2009.12.017 (2009).
30. Shapira, S. D. et al. A physical and regulatory map of host-influenza interactions
reveals pathways in H1N1 infection. Cell 139, 1255–1267, doi:10.1016/
j.cell.2009.12.018 (2009).
31. Karlas, A. et al. Genome-wide RNAi screen identifies human host factors crucial
for influenza virus replication. Nature 463, 818–822, doi:10.1038/nature08760
(2010).
32. Konig, R. et al. Human host factors required for influenza virus replication.Nature
463, 813–817, doi:10.1038/nature08699 (2010).
33. Lacaze, P. et al. Combined genome-wide expression profiling and targeted RNA
interference in primary mouse macrophages reveals perturbation of
transcriptional networks associated with interferon signalling. BMCGenomics 10,
372, doi:10.1186/1471-2164-10-372 (2009).
34. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7
MyD88-dependent signaling pathway. Nat Immunol 3, 196–200, doi:10.1038/
ni758 (2002).
35. Jurk, M. et al. Human TLR7 or TLR8 independently confer responsiveness to the
antiviral compound R-848. Nat Immunol 3, 499, doi:10.1038/ni0602-499 (2002).
36. Wall, E. A. et al. Suppression of LPS-induced TNF-alpha production in
macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal 2, ra28,
doi:10.1126/scisignal.2000202 (2009).
Acknowledgments
This work was generously supported by the Intramural Research Program of the National
Institute of Allergy and Infectious Diseases and the National Cancer Institute. We thank
Ron Germain and colleagues in the Laboratory of Systems Biology for helpful discussions
and critical reading of the manuscript.
Author contributions
N.L. generated and optimized the RAWG9 cell line and developed and validated the RAW
G9 siRNA delivery protocols. J.S. optimized the THP1 B5 cell line, developed and validated
the THP1 B5 siRNA delivery protocol and generated the bacterial infection data in the
RAWG9 cells. Z.L.B. carried out the ligand panel and dose-response testing of the RAWG9
cell line. Z.W. prepared the human TNF-a dual luciferase lentiviral plasmid and generated
the parent cell line for the THP1 B5 clone. S.A.K. developed and optimized the B.
cenocepacia bacterial infection protocol and generated the THP1 B5 infection data. S.P.J.
generated the PMAoptimization data in Fig. 1. S.P.J. and B.L. evaluated gene knockdown by
qPCR.M.H.S. developed the live cell imaging protocol for the RAWG9 clone and generated
Supplementary Videos 1–3. I.D.C.F. designed the study, generated plasmid constructs and
wrote the manuscript.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Li, N. et al. Development of a cell system for siRNA screening of
pathogen responses in human and mouse macrophages. Sci. Rep. 5, 9559; DOI:10.1038/
srep09559 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9559 | DOI: 10.1038/srep09559 10
